XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2025
Segment Information  
Schedule of Segment information

When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

2025

    

2024

2025

    

2024

Program expenses related to clinical-stage product candidates

$

(4,228,642)

$

(4,676,084)

$

(8,445,857)

$

(10,588,112)

Program expenses related to preclinical and discovery programs

(49,714)

(169,176)

(80,313)

(277,514)

Personnel-related expenses (including stock-based compensation)

(1,496,642)

(2,333,028)

(2,894,516)

(3,527,715)

General and administrative professional and consultant fees

(292,649)

(389,485)

(737,514)

(758,838)

Other segment items¹

(203,806)

(194,865)

(395,934)

(420,266)

Interest income

191,395

25,978

379,007

70,146

Other non-cash income (expense) items²

(140,000)

2,716,248

418,000

9,414,940

Net Loss

$

(6,220,058)

$

(5,020,412)

$

(11,757,127)

$

(6,087,359)

¹ Other segment items included in net loss include insurance expenses, rent expense, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses.

² Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.